Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

Merck–Revolution Medicines Takeover Talks Collapse Over Price Dispute

Investors shift focus to Revolution’s late‑stage cancer drug milestones after the deal prospects faded.

Wegovy Pill Debuts to Strong U.S. Demand as Next‑Gen Obesity Drugs Near Decisions

Sanofi Pushes Amlitelimab Toward 2026 Filings After Mixed Phase 3 Readouts

FDA Delays Two Drugs in National Priority Voucher Program After Safety, Efficacy Flags

Alumis TYK2 Pill Hits Phase 3 Goals in Psoriasis as Stock Jumps and $175 Million Offering Is Planned

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

Argenx Sets CEO Succession, Tapping COO Karen Massey as Tim Van Hauwermeiren Moves to Chair

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

FDA Grants Priority Review to Axsome’s AXS-05 for Alzheimer’s Agitation, Sets April 30 PDUFA Date

Insilico Medicine Surges on Hong Kong Debut After HK$2.3 Billion IPO

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

EU Regulator Backs Myqorzo for Obstructive Hypertrophic Cardiomyopathy

Daré Bioscience Launches Topical Sildenafil Cream for Female Arousal

Ianalumab Plus Eltrombopag Extends Disease Control in Phase 3 ITP Study Published in NEJM

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML